stonks4u
Log inSign up free
ATTO logo

ATTO Attovia Therapeutics, Inc.

NASDAQ · Biotechnology · Healthcare

$20.26
+0.40 (+2.01%)

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory disease…

Market Cap: $871.79Mwww.attovia.com

Price

No data yet.

Signal Score (90d)

100
100
Aug 17Aug 17

Quote

Day Range
$19.85 – $20.61
52-Week Range
$16.15 – $22.79
Volume
$77.7K
Market Cap
$871.79M
50-Day Avg
$19.75
200-Day Avg
$19.75
Prev Close
$19.86
Open
$19.85

Valuation & Ratios

P/E Ratio
-15.42
EPS
$-1.41
P/B Ratio
6.25
P/S Ratio
698.03
Debt/Equity
0.03
Current Ratio
14.20
Dividend Yield
+0.0%
Gross Margin
+40.4%

Returns & Efficiency

Return on Equity
-40.2%
Return on Assets
-36.5%
FCF Yield
-6.5%
EV/EBITDA
-13.67

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$1.35M$-60.63M$-1.42
2024$0.00$-39.80M$-1.05

Social Signal Score

50
5d
51
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Insider trading

Open-market buys and sells by ATTO officers and directors.

Bought
$52.4m

9 trades

Sold
$4.5m

46 trades

  • Walsh Colinbought
    director·500,000 @ $17.00·$8.5m·Aug 6, 2026·filing
  • Goldman Sachs Group Incbought
    other: Former 10% Owner·500,000 @ $17.00·$8.5m·Aug 6, 2026·filing
  • Venbio Global Strategic Fund Iv, L.p.bought
    10 percent owner·382,352 @ $17.00·$6.5m·Aug 6, 2026·filing
  • Redmile Group, Llcbought
    10 percent owner·400,000 @ $17.00·$6.8m·Aug 6, 2026·filing
  • Redmile Group, Llcbought
    10 percent owner·200,000 @ $17.00·$3.4m·Aug 6, 2026·filing
  • Sanofibought
    10 percent owner·300,000 @ $17.00·$5.1m·Aug 6, 2026·filing
  • Frazier Life Sciences Xi, L.p.bought
    10 percent owner·588,235 @ $17.00·$10.0m·Aug 6, 2026·filing
  • Walsh Colinbought
    director·85,000 @ $21.00·$1.8m·Aug 5, 2026·filing

45 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

ATTOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • News247wallst.com·5h ago·Neutral

    Meet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the Source Attovia Therapeutics (NASDAQ:ATTO) has arrived on public markets with a pipeline built entirely on one bet: that a biparatopic antibody platform called Attobody can turn well-validated immunology targets into next-generation biologics.

    View source ↗